Panbela Therapeutics (NASDAQ:PBLA) (NASDAQ: PBLA) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for oncology indications. Headquartered in Indianapolis, Indiana, Panbela applies its proprietary Super BioAvailable™ (SBP) platform to enhance the delivery and efficacy of small-molecule treatments. The company’s research and development efforts are centered on improving outcomes in difficult-to-treat cancers through innovative formulations designed to maximize bioavailability and therapeutic index.
The company’s lead product candidate, SBP-101, is a polyamine analogue under investigation for use in metastatic pancreatic cancer, high-grade serous ovarian cancer and other solid tumors. SBP-101 operates by targeting polyamine metabolic pathways that are frequently dysregulated in tumor cells. Panbela has advanced SBP-101 into multiple Phase 2 clinical trials in North America and Europe and has reported favorable safety and tolerability profiles to date. In parallel, the company is developing nevanimibe (formerly under the designation NP-001), an oral small molecule designed to inhibit a key enzyme in cholesterol biosynthesis for the treatment of adrenocortical carcinoma.
Panbela maintains a diversified intellectual property portfolio, securing patent protection for its SBP delivery platform and related compounds across major markets including the United States, Europe, Canada and Australia. The company collaborates with clinical research organizations and academic medical centers to conduct multicenter studies and expand its development footprint. Panbela’s global trial sites enable the company to gather a broad spectrum of safety and efficacy data while positioning its programs for potential regulatory filings in multiple jurisdictions.
Leadership at Panbela is spearheaded by President and Chief Executive Officer James E. Culver, Ph.D., whose background in oncology research and drug development guides the company’s strategic direction. Supported by a management team with expertise in clinical operations, regulatory affairs and finance, Panbela has steadily progressed its pipeline since its founding, leveraging both in-house capabilities and external partnerships. The company remains committed to advancing its novel platform technologies to address unmet needs in oncology.
